{
    "clinical_study": {
        "@rank": "82342", 
        "acronym": "SO VI", 
        "arm_group": [
            {
                "arm_group_label": "Drug eluting stent (BioMatrix Flex)", 
                "arm_group_type": "Experimental", 
                "description": "Device: Percutaneous coronary intervention with implantation of drug eluting stent (BioMatrix Flex)"
            }, 
            {
                "arm_group_label": "Drug eluting stent (Resolute Integrity)", 
                "arm_group_type": "Experimental", 
                "description": "Device: Percutaneous intervention with implantation of drug eluting coronary stent (Resolute Integrity)"
            }
        ], 
        "brief_summary": {
            "textblock": "To perform a randomized comparison between the BioMatrix Flex\u2122 and the Resolute Integrity\u00ae\n      stents in the treatment of unselected patients with ischemic heart disease."
        }, 
        "brief_title": "SORT-OUT VI - Randomized Clinical Comparison of Biomatrix Flex\u00ae and Resolute Integrity\u00ae", 
        "completion_date": {
            "#text": "July 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Coronary Artery Disease", 
            "Angina Pectoris"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Angina Pectoris", 
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease"
            ]
        }, 
        "detailed_description": {
            "textblock": "SORT OUT VI is a randomized, multicenter, all-comer, two-arm, non-inferiority trial\n      comparing the Biolimus-eluting Biomatrix Flex and the Zotarolimus-eluting Medtronic Resolute\n      Integrity in treatment of atherosclerotic coronary artery lesions.\n\n      Primary Endpoint:\n\n      Target lesion failure within 12 months of stent implantation (combination of cardiac death,\n      myocardial infarction (not index procedure related) not related to other than index lesion\n      or target lesion revascularization).\n\n      Secondary Endpoints:\n\n      Individual components of the primary end point comprised the secondary end points and stent\n      thrombosis rate according to the Academic Research Consortium definition (see protocol for\n      further specification of secondary endpoints).\n\n      Clinically driven event detection will be used to avoid study-induced reinterventions. Data\n      on mortality, hospital admission, coronary angiography, repeat percutaneous coronary\n      intervention, and coronary bypass surgery will be obtained for all randomly allocated\n      patients from the following national Danish administrative and healthcare registries: the\n      Civil Registration System; the Western Denmark Heart Registry; the Danish National Registry\n      of Patients, which maintains records on all hospitalizations in Denmark; and the Danish\n      Registry of Causes of Death"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients aged 18 years or over with chronic stable coronary artery disease or acute\n             coronary syndromes, and at least one coronary artery lesion with more than 50%\n             diameter stenosis, requiring treatment with a drug-eluting stent.\n\n        Exclusion Criteria:\n\n          -  life expectancy of less than one year\n\n          -  an allergy to aspirin, clopidogrel, ticagrelor, prasugrel, sirolimus, or biolimus\n\n          -  participation in another randomized trial\n\n          -  inability to provide written informed consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "2800", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01956448", 
            "org_study_id": "M-20110037"
        }, 
        "intervention": {
            "arm_group_label": [
                "Drug eluting stent (BioMatrix Flex)", 
                "Drug eluting stent (Resolute Integrity)"
            ], 
            "description": "Device: Percutaneous intervention with implantation of drug eluting coronary stent (Resolute Integrity)", 
            "intervention_name": "Drug eluting stent", 
            "intervention_type": "Device", 
            "other_name": [
                "BioMatrix Flex - biolimus eluting stent", 
                "Resolute - zotarolimus eluting stent"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Percutaneous coronary intervention", 
            "DES", 
            "Angina pectoris", 
            "Stent"
        ], 
        "lastchanged_date": "October 6, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Skejby", 
                        "country": "Denmark", 
                        "state": "Aarhus N", 
                        "zip": "8200"
                    }, 
                    "name": "Aarhus University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aalborg", 
                        "country": "Denmark", 
                        "zip": "9000"
                    }, 
                    "name": "Aalborg University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Odense", 
                        "country": "Denmark", 
                        "zip": "5000"
                    }, 
                    "name": "Odense University Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Clinical Comparison of Biomatrix Flex\u00ae and Resolute Integrity\u00ae Coronary Stents in Non-selected Patients With Ischemic Heart Disease The SORT OUT VI Study*", 
        "overall_official": {
            "affiliation": "Aalborg Universityhospital", 
            "last_name": "Jan Ravkilde, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Denmark: Danish Dataprotection Agency", 
                "Denmark: Danish Medicines Agency", 
                "Denmark: Ethics Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Device-related combined endpoint hierarchically:\ncardiac death, non-index procedure related acute myocardial infarction not clearly related to another lesion than the target lesion (new revascularization by PCI or CABG) within 12 months.", 
            "measure": "Device-related combined endpoint", 
            "safety_issue": "Yes", 
            "time_frame": "1,2,3 and 5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01956448"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Aarhus University Hospital Skejby", 
            "investigator_full_name": "Evald Hoej Christiansen", 
            "investigator_title": "MD, DMSc", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Device success rate", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Procedure success rate", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Procedure time", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Fluoroscopy time", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Amount of contrast", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Combined endpoint of cardiac death, non-index procedure related acute myocardial infarction, not clearly related to another lesion than target lesion, target lesion revascularisation", 
                "safety_issue": "Yes", 
                "time_frame": "30 days"
            }, 
            {
                "measure": "Target lesion revascularisation", 
                "safety_issue": "Yes", 
                "time_frame": "1,2,3 and 5 years"
            }, 
            {
                "measure": "Death and myocardial infarction", 
                "safety_issue": "Yes", 
                "time_frame": "1 and 12 months"
            }, 
            {
                "measure": "Stent thrombosis", 
                "safety_issue": "Yes", 
                "time_frame": "1,2,3 and 5 years"
            }, 
            {
                "measure": "Device-related combined endpoint hierarchically cardiac death, non-index procedure related AMI, not clearly related to another lesion than target lesion", 
                "safety_issue": "Yes", 
                "time_frame": "2,3 and 5 years"
            }, 
            {
                "measure": "Patient-related combined endpoint hierarchically: all-cause death, non-index procedure related acute myocardial infarction, all new revascularizations", 
                "safety_issue": "Yes", 
                "time_frame": "1,2,3 and 5 years"
            }, 
            {
                "measure": "All-cause death", 
                "safety_issue": "Yes", 
                "time_frame": "10 years"
            }
        ], 
        "source": "Aarhus University Hospital Skejby", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Biosensors International", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Medtronic Cardiovascular", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Aarhus University Hospital Skejby", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}